A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

This study is comparing two treatment approaches for people with liver cancer (hepatocellular carcinoma) that cannot be surgically removed or has not spread. One group receives a standard procedure called TACE (a targeted chemotherapy delivered directly to the liver) combined with two immunotherapy/anti-tumor drugs. The other group receives TACE alone. **You may be eligible if...** - You have confirmed liver cancer that cannot be cured by surgery, transplant, or ablation - Your cancer has not spread to other organs - Your liver function is relatively preserved (Child-Pugh class A) - Your overall health status is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have had a liver transplant or hepatic encephalopathy (brain confusion from liver disease) - You have uncontrolled high blood pressure or a recent blood clot - You have had significant bleeding in the last 6 months - You have both hepatitis B and C at the same time Talk to your doctor to see if this trial is right for you.